- Theravance Biopharma (TBPH, Financial) to announce Q1 2025 financial results on May 8, 2025.
- The company will host a conference call and webcast at 5:00 pm EDT.
- Replay of the webcast will be available until June 7, 2025.
Theravance Biopharma, Inc. (TBPH) is set to release its first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025, following the market close. Investors and interested parties can gain insights into the company's performance and strategic direction during a conference call and simultaneous webcast scheduled for 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) on the same day.
Participants can join the live call by dialing (800) 715-9871 from the United States or (646) 307-1963 for international calls with the Conference ID 3369474. Additionally, the webcast will be accessible through the Investors section of Theravance Biopharma's website, where it will remain available for replay until June 7, 2025.
Theravance Biopharma, notable for its development of FDA-approved YUPELRI® (revefenacin) inhalation solution for COPD maintenance treatment, continues to focus on delivering innovative medical solutions. Its investigational therapy, Ampreloxetine, a potential first-in-class treatment for symptomatic neurogenic orthostatic hypotension in Multiple System Atrophy (MSA) patients, exemplifies the company's commitment to advancing medical research.
